Your browser doesn't support javascript.
loading
Impact of SARS-CoV-2 ORF6 and its variant polymorphisms on host responses and viral pathogenesis.
Thomas Kehrer; Anastasija Cupic; Chengjin Ye; Soner Yildiz; Mehdi Bouhhadou; Nicholas A. Crossland; Erika Barrall; Philip Cohen; Anna Tseng; Tolga Çağatay; Raveen Rathnasinghe; Daniel Flores; Sonia Jangra; Fahmida Alam; Nacho Mena; Sadaf Aslam; Anjali Saqi; Arturo Marin; Magdalena Rutkowska; Manisha R. Ummadi; Giuseppe Pisanelli; R. Blake Richardson; Ethan C. Veit; Jacqueline M.A. Fabius; Margaret Soucheray; Benjamin J. Polacco; Matthew J. Evans; Danielle L. Swaney; Ana S. Gonzalez-Reiche; Emilia M. Sordillo; Harm van Bakel; Viviana Simon; Lorena Zuliani-Alvarez; Beatriz M. A. Fontoura; Brad R. Rosenberg; Nevan J. Krogan; Luis Martinez-Sobrido; Adolfo García-Sastre; Lisa Miorin.
Affiliation
  • Thomas Kehrer; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
  • Anastasija Cupic; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
  • Chengjin Ye; Texas Biomedical Research Institute, San Antonio, Texas, USA.
  • Soner Yildiz; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
  • Mehdi Bouhhadou; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA, USA
  • Nicholas A. Crossland; Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, Massachusetts, USA.
  • Erika Barrall; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
  • Philip Cohen; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
  • Anna Tseng; Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, Massachusetts, USA.
  • Tolga Çağatay; Department of Cell Biology, University of Texas Southwestern Medical Center, Dallas, TX.
  • Raveen Rathnasinghe; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
  • Daniel Flores; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
  • Sonia Jangra; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
  • Fahmida Alam; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
  • Nacho Mena; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
  • Sadaf Aslam; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
  • Anjali Saqi; Department of Pathology and Cell Biology, Columbia University Medical Center, New York, New York, USA.
  • Arturo Marin; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
  • Magdalena Rutkowska; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
  • Manisha R. Ummadi; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA, USA
  • Giuseppe Pisanelli; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
  • R. Blake Richardson; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
  • Ethan C. Veit; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
  • Jacqueline M.A. Fabius; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA, USA
  • Margaret Soucheray; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA, USA
  • Benjamin J. Polacco; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA, USA
  • Matthew J. Evans; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
  • Danielle L. Swaney; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA, USA
  • Ana S. Gonzalez-Reiche; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Emilia M. Sordillo; Department of Pathology, Molecular, and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
  • Harm van Bakel; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Viviana Simon; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
  • Lorena Zuliani-Alvarez; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA, USA
  • Beatriz M. A. Fontoura; Department of Cell Biology, University of Texas Southwestern Medical Center, Dallas, TX.
  • Brad R. Rosenberg; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
  • Nevan J. Krogan; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA, USA
  • Luis Martinez-Sobrido; Texas Biomedical Research Institute, San Antonio, Texas, USA.
  • Adolfo García-Sastre; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
  • Lisa Miorin; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
Preprint in En | PREPRINT-BIORXIV | ID: ppbiorxiv-512708
ABSTRACT
We and others have previously shown that the SARS-CoV-2 accessory protein ORF6 is a powerful antagonist of the interferon (IFN) signaling pathway by directly interacting with Nup98-Rae1 at the nuclear pore complex (NPC) and disrupting bidirectional nucleo-cytoplasmic trafficking. In this study, we further assessed the role of ORF6 during infection using recombinant SARS-CoV-2 viruses carrying either a deletion or a well characterized M58R loss-of-function mutation in ORF6. We show that ORF6 plays a key role in the antagonism of IFN signaling and in viral pathogenesis by interfering with karyopherin(importin)-mediated nuclear import during SARS-CoV-2 infection both in vitro, and in the Syrian golden hamster model in vivo. In addition, we found that ORF6-Nup98 interaction also contributes to inhibition of cellular mRNA export during SARS-CoV-2 infection. As a result, ORF6 expression significantly remodels the host cell proteome upon infection. Importantly, we also unravel a previously unrecognized function of ORF6 in the modulation of viral protein expression, which is independent of its function at the nuclear pore. Lastly, we characterized the ORF6 D61L mutation that recently emerged in Omicron BA.2 and BA.4 and demonstrated that it is able to disrupt ORF6 protein functions at the NPC and to impair SARS-CoV-2 innate immune evasion strategies. Importantly, the now more abundant Omicron BA.5 lacks this loss-of-function polymorphism in ORF6. Altogether, our findings not only further highlight the key role of ORF6 in the antagonism of the antiviral innate immune response, but also emphasize the importance of studying the role of non-spike mutations to better understand the mechanisms governing differential pathogenicity and immune evasion strategies of SARS-CoV-2 and its evolving variants. ONE SENTENCE SUMMARYSARS-CoV-2 ORF6 subverts bidirectional nucleo-cytoplasmic trafficking to inhibit host gene expression and contribute to viral pathogenesis.
License
cc_no
Full text: 1 Collection: 09-preprints Database: PREPRINT-BIORXIV Type of study: Experimental_studies Language: En Year: 2022 Document type: Preprint
Full text: 1 Collection: 09-preprints Database: PREPRINT-BIORXIV Type of study: Experimental_studies Language: En Year: 2022 Document type: Preprint